Pineal hormone / MT1–MT2 receptor agonist
Melatonin
at MT1 and MT2 GPCRs that phase-shift circadian clocks and promote sleep propensity; antioxidant radical-scavenging is additional pharmacology at higher concentrations.
Primary Mechanism of Action
Clinical / Scientific
Melatonin activates MT1 and MT2 receptors in the suprachiasmatic nucleus and other tissues, reducing SCN neuronal firing (MT1) and shifting clock phase (MT2). Direct antioxidant effects occur at concentrations that may exceed nocturnal physiologic levels.
Pathway Targets
MT1 receptor
Scientific explanation
Sleep-related SCN inhibition.
MT2 receptor
Scientific explanation
Circadian phase shifting.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Clock and sleep signalling
Target to downstream effect: MT1/MT2 agonism → SCN firing / clock-gene modulation → Increased sleep propensity and phase alignment
Mechanistically Relevant Repurposed & Adjunctive Applications
Circadian and sleep-onset support
EstablishedMechanistic rationale
Widely used for jet lag and some sleep-onset problems; regulatory status (supplement vs medicine) varies.
Antioxidant / mitochondrial hypotheses
Mechanistically PlausibleMechanistic rationale
Radical scavenging is real chemistry; clinical outcomes from that property are not automatically proven.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| MT1 | Agonism | Sleep propensity | Established mechanism |
| MT2 | Agonism | Circadian phase | Established mechanism |
Mechanistic Interaction Considerations
Sedative combinations and CYP1A2-related interactions may occur. Not a substitute for assessment of sleep disorders.
In Plain Language
Melatonin is the darkness hormone. It tells brain clock receptors that night has arrived, which can make it easier to fall asleep and can shift the body clock.
Oncology Mechanistic Relevance
Cancers in the atlas where this compound has a mapped mechanistic rationale. Evidence tiers are not equivalent and do not imply treatment.
Circadian and antioxidant chemistry with adjunctive hypotheses. Not an antineoplastic standard.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.